PM360 2022 Trailblazer Awards Specialty Pharma/Biotech CEO of the Year Timothy R. Wright

Timothy R. Wright, Chief Executive Officer, MIMEDX

Tim Wright has dedicated over 25 years of service to the life sciences and medical technology communities. His experience has taught him that culture guides performance, and this is why his leadership has been so effective. From the genesis of DuPont-Merck Pharma to his work in transformational placental biologics innovation at MIMEDX, few in the industry have his vast experience across the industry ecosystem. As a business leader and community builder, Tim recognizes that when imagination and innovation combine, science can do its best work to address people’s pressing health needs.

After years of leadership at various pharmaceutical headliners, Tim leaned into the personalized medical technology approach at MIMEDX to develop the best possible solutions to evolving patient needs in often underserved populations, where a one-size-fits-all approach no longer works. MIMEDX has developed proprietary human placental tissue graft products to treat chronic wounds and other degenerative muscular conditions. Under Tim’s leadership, MIMEDX advanced its clinical and research programs, becoming a pioneer in innovative regenerative medicine. He made the company’s clear goal to provide physicians, nurses, and other HCPs with the evidence-based solutions needed to promote healing and restore patient quality of life when treating wounds or persistent disease states.

Always looking forward, Tim led the company to invest in further innovations in amniotic tissue science and biologics to directly treat musculoskeletal degeneration. His goal was to push the boundaries of science advancements while ensuring its safety and efficacy, while also making an effort to reach out to allies in the space to bring these advancements to HCPs, advocacy organizations, and underserved patients with evolving needs. He knows that teams need to be dedicated and adaptable to create products that become more valuable as the population continues to increase in age and rates of diabetes climb along with the associated higher susceptibility to non-healing, chronic wounds.

Tim is now exploring new opportunities as MIMEDX announced a leadership transition on September 6, 2022 with K. Todd Newton taking over as interim CEO while the company begins its search for a replacement. In a statement, Tim said, “It has been a privilege to serve as the CEO of MIMEDX, and I am proud of all that we have accomplished together to advance the company and improve the lives and treatment options for patients. I wish the team well as they begin a new chapter at MIMEDX.”

Ads

You May Also Like

PM360 2023 Trailblazer Awards App/Digital Solution or Suite Gold Winner Neurocrine Biosciences, Inc. and Level Ex

Discover TD Solution (Neurocrine Biosciences, Inc. and Level Ex) In a groundbreaking collaboration, Neurocrine ...

PM360 2021 Trailblazer Awards Infectious Disease Brand Champion Megan Shultis

Megan Shultis, Director, U.S. Consumer Lead, Adult Pneumococcal Vaccine Marketing, Pfizer Due to the ...